Positive results from Phase I clinical trial in acne
April 15, 2008 02:00 ET
|
Summit Therapeutics plc
Summit Corporation plc
("Summit plc" or "the Company")
POSITIVE RESULTS FROM PHASE I CLINICAL TRIAL OF SMT D002 FOR THE TREATMENT OF SEBORRHOEA, A PRIMARY CAUSE OF ACNE
SMT D002...
Zebrafish Data Presented at International Conferences
April 09, 2008 04:30 ET
|
Summit Therapeutics plc
Summit Corporation plc
("Summit" or "the Company")
SUMMIT PRESENTS THE BENEFITS ZEBRAFISH BRING TO DRUG DISCOVERY AND DEVELOPMENT AT TWO INTERNATIONAL CONFERENCES
Oxford, UK, 9...
Total voting rights
April 01, 2008 11:14 ET
|
Summit Therapeutics plc
Summit Corporation plc
("Summit plc" or "the Company")
Oxford, UK, 2 April 2008 - Summit Corporation plc (AIM: SUMM) notifies the market of the following information in order to conform...
Additional Listing
March 25, 2008 07:15 ET
|
Summit Therapeutics plc
Summit Corporation plc
("Summit plc" or "the Company")
ADDITIONAL LISTING
Oxford, UK, 25 March 2008 - Summit Corporation plc (AIM: SUMM), a leading UK biotechnology company,...
Re Contract
February 21, 2008 02:00 ET
|
Summit Therapeutics plc
Summit Corporation plc
("Summit plc" or "the Company")
SUMMIT PLC ANNOUNCES CONTRACT WINS BY DEXTRA CARBOHYDRATE SERVICE BUSINESS
£500,000 GMP service contracts signed with potential...
PAYMENT OF NON-EXECUTIVE DIRECTORS' FEES IN SHARES
February 05, 2008 11:17 ET
|
Summit Therapeutics plc
Oxford, UK, 5 February 2008 - Summit Corporation plc (AIM: SUMM) today announces that two Non-executive Directors of the Company have taken all or part of their fees for the quarter ended 31 January...